They're like a fire that's stopped burning but still radiates heat.
In the long effort to understand why cancer persists even after treatment appears to have worked, scientists at the MRC Laboratory of Medical Sciences and Imperial College London have identified a hidden vulnerability in so-called 'zombie' cells — dormant tumor cells that, though no longer dividing, continue to poison their surroundings. By targeting a protective protein called GPX4, researchers found they could trigger a form of iron-driven cell death in these cells, dismantling a quiet but corrosive force within tumors. The discovery, tested across multiple mouse cancer models, suggests that what medicine once considered a treatment endpoint may itself be a source of ongoing harm — and now, a potential target.
- Senescent 'zombie' cells accumulate in tumors after chemotherapy and, though they've stopped dividing, actively secrete molecules that drive cancer spread, metastasis, and immune dysfunction.
- A screen of 10,000 compounds revealed that three drugs targeting the protein GPX4 could selectively kill these senescent cells by unleashing ferroptosis — a form of cell death fueled by toxic iron buildup that GPX4 normally suppresses.
- In three separate mouse cancer models, these senolytic compounds shrank tumors and extended survival, signaling that the approach may work across multiple cancer types.
- Researchers are now investigating whether these drugs also reactivate immune cells that fight cancer, and which patient populations — particularly those with high GPX4 tumor levels — stand to benefit most from combining this method with existing therapies.
Cancer cells that stop dividing are not harmless. A team at the MRC Laboratory of Medical Sciences and Imperial College London has found a precise way to exploit what makes these dormant cells vulnerable — and eliminate them.
Senescent, or 'zombie,' cells accumulate in tumors after chemotherapy. They no longer grow, but they secrete molecules that push neighboring cells toward aggression, spread, and immune dysfunction — like a fire that's stopped burning but still radiates heat. Researchers set out to find drugs that could selectively destroy them.
Screening 10,000 compounds, the team identified four candidates. Three targeted a protein called GPX4, which shields senescent cells from ferroptosis — a form of cell death triggered when iron and reactive oxygen species reach dangerous levels. Senescent cells are saturated with both, surviving only because they produce enormous amounts of GPX4 to hold ferroptosis at bay. When researchers blocked GPX4, that defense collapsed and the cells died. In three different mouse cancer models, the compounds shrank tumors and extended survival across cancer types.
Postdoctoral researcher Mariantonietta D'Ambrosio, who led the study published in Nature Cell Biology, noted how the field's understanding has shifted. Chemotherapy was designed to push cancer cells into senescence to halt tumor growth — but over time it became clear these cells actively reshape their environment in ways that make cancer worse. Removing them entirely opens a new therapeutic angle.
The next phase will examine whether these drugs also awaken immune cells that naturally fight cancer, and identify which patients — particularly those with high GPX4 tumor levels — might benefit most from combining this approach with existing chemotherapy and immunotherapy.
Cancer cells that stop dividing are not harmless. Scientists have long known this, but a team at the MRC Laboratory of Medical Sciences and Imperial College London has now found a precise way to exploit what makes these cells tick—and kill them.
These dormant cells, called senescent or "zombie" cells, accumulate in tumors after chemotherapy. They don't grow anymore, which sounds like a win. But they secrete molecules that nudge neighboring cells toward aggression, spread, and immune dysfunction. They're like a fire that's stopped burning but still radiates heat. Researchers wanted to find drugs that could selectively eliminate them, a class of treatment known as senolytic drugs.
The team screened 10,000 compounds looking for ones that would kill senescent cells while leaving healthy cells alone. From that vast library, four candidates emerged. Three of them targeted a protein called GPX4, which acts as a shield inside senescent cells. This protein prevents a particular type of cell death called ferroptosis—a process triggered when iron and harmful molecules called reactive oxygen species accumulate to dangerous levels. Senescent cells are drowning in iron and oxidative damage. They survive only because they produce massive amounts of GPX4 to keep ferroptosis at bay. It's like taking painkillers to keep running on a broken ankle. The injury is still there; the drug just masks it.
When researchers blocked GPX4, that protective system collapsed. Ferroptosis became inevitable. The senescent cells died, and the tumor lost a population of cells that had been actively promoting its own growth. In three different mouse models of cancer, these new compounds shrank tumors and extended survival. The effect was consistent across different cancer types, suggesting the approach has broad potential.
Mariantonietta D'Ambrosio, the postdoctoral researcher who led the study published in Nature Cell Biology, explained how understanding of senescent cells has shifted. For decades, scientists saw them as beneficial—after all, they don't divide, which is the core problem in cancer. Chemotherapy was designed to push cells into senescence as a way to stop tumor expansion. But over time, the darker side became clear. These cells don't just sit quietly. They actively reshape their environment in ways that make cancer worse. Finding a way to remove them entirely opens a new therapeutic angle.
The next phase of research will examine how these drugs affect the immune system. Do they not only remove the harmful senescent cells but also awaken the immune cells that naturally fight cancer? Researchers also need to understand which patients might benefit most. If a patient undergoing chemotherapy has tumors with high GPX4 levels, combining this new approach with existing drugs could improve outcomes. The work suggests that senescent cells, long overlooked as a treatment target, represent a significant opportunity to strengthen cancer therapy alongside chemotherapy and immunotherapy.
Notable Quotes
Senescent cells secrete factors that influence neighboring cells and induce proliferation, metastasis, and recruitment of aggressive immune responses that make the tumor more aggressive.— Mariantonietta D'Ambrosio, lead researcher
Targeting senescence is a huge opportunity for cancer treatments and can play a supporting role alongside chemotherapy and immunotherapy.— Mariantonietta D'Ambrosio
The Hearth Conversation Another angle on the story
So these zombie cells—they're not growing, but they're making the cancer worse?
Exactly. They've stopped dividing, which is what we want, but they're secreting factors that encourage nearby cells to grow and spread. It's like they're stuck in place but still poisoning the neighborhood.
And the new drugs kill them by blocking a protein called GPX4?
Right. GPX4 is their lifeline. These senescent cells are loaded with iron and oxidative damage—conditions that would normally kill any cell. GPX4 is what keeps them alive despite that. Block it, and ferroptosis kicks in. The cell can't survive the damage anymore.
They tested 10,000 compounds to find this?
Yes, a massive screening effort. They were looking for compounds that would selectively kill senescent cells without harming normal ones. Four candidates worked, and three of them targeted GPX4.
Did it actually work in real tumors?
In mouse models, yes. The drugs reduced tumor size and improved survival across three different cancer types. But we're still early. The next question is whether these drugs also activate the immune system to fight cancer more effectively.
Could this replace chemotherapy?
Unlikely. The real promise is in combination. If a patient's tumor has high GPX4 levels, you could use this alongside chemotherapy to improve the effect. It's a supporting strategy, not a replacement.
What happens next?
They need to understand which patients benefit most and how the immune system responds. Then clinical trials. But the basic principle is proven: senescent cells have a fatal weakness, and we now know how to exploit it.